Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $6.3 million.

  • Cumberland Pharmaceuticals' Other Non-Current Liabilities fell 2.29% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 2.29%. This contributed to the annual value of $6.3 million for FY2024, which is 2.38% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $6.3 million for FY2024, which was down 2.38% from $6.5 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $7.9 million for FY2020, and its period low was $6.3 million during FY2024.
  • For the 3-year period, Cumberland Pharmaceuticals' Other Non-Current Liabilities averaged around $6.8 million, with its median value being $6.5 million (2023).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Other Non-Current Liabilities rose by 1.28% in 2022, and later declined by 14.92% in 2023.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Other Non-Current Liabilities stood at $7.9 million in 2020, then declined by 4.76% to $7.5 million in 2021, then grew by 1.28% to $7.6 million in 2022, then declined by 14.92% to $6.5 million in 2023, then decreased by 2.38% to $6.3 million in 2024.